Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting
Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting
Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…Abstract Number: 2865 • 2014 ACR/ARHP Annual Meeting
The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin
Background/Purpose Recently we showed that FXa reactive IgG in patients with the antiphospholipid syndrome (APS) displayed higher avidity binding to FXa and had greater functional…Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting
External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß2-Glycoprotein I. a Prospective Multicentre Cohort Study
Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications. However, the interaction of…Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…